Corcept Therapeutics reported robust Q2 2026 results with $256.1 million in revenue, a 32% increase year-over-year, driven by a $47.6 million launch of its oncology drug Lifyorli. The company is evolving from a single-focus endocrine treatment to a multi-engine growth platform, supported by new studies showing Cushing's disease is more common than previously thought, which expands the market potential significantly. Despite higher launch expenses, Corcept maintained profitability and shows promising pipeline options and durable fundamentals, leading to a positive outlook for the second half of 2026.
TPG RE Finance Trust (TRTX) is rated Sell due to its inability to cover dividends with distributable earnings, reporting $0.23 per share against a $0.24 dividend in Q2. Despite higher loan balances, net interest income dropped 5.9% year-over-year, pr...
Leidos and investment firm Altaris have completed their joint venture to create a US-based company under the Analogic brand, combining security screening technologies for airports, borders, and critical infrastructure worldwide. Leidos retains a sign...
MicroStrategy, now rebranded as Strategy, purchased only 334 Bitcoin last week for $28.7 million, a much smaller amount compared to previous weeks. Instead, it spent $176.3 million buying back its preferred stock, which pays a 12% dividend, signaling...
Once Upon a Farm has expanded its product line with new organic Electrolyte Blends designed to support hydration and electrolyte balance in active children. These pouches use real food ingredients like fruits, veggies, coconut water, and sea salt, of...
EPAM Systems has introduced a new AI service designed to support next-generation frontier AI models in handling complex enterprise workflows more reliably. This offering leverages EPAM's extensive experience and partnerships with leading AI labs like...
